Journal of Renal Nutrition
Volume 12, Issue 2 , Pages 76-86 , April 2002

Probiotics and prebiotics: A brief overview

References 

  1. In:  Thomas PR,  Earl R editor. Institute of Medicine, National Academy of Sciences: Opportunities in the nutrition and food sciences. Washington, DC: National Academy Press; 1994;p. 109
  2. Gibson GR. Dietary modulation of the human gut microbiota using prebiotics. Br J Nutr. 1998;80(suppl):209–212
  3. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;130:396–402
  4. Macfariane GT, Cummings JH. Probiotics and prebiotics: Can regulating the activities of intestinal bacteria benefit health?. Br Med J. 1999;318:999–1003
  5. Gibson G, Roberfroid MB. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412
  6. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA. 1996;275:870–876
  7. Havenaar R, Huis in't Veld JHJ. Probiotics: A general view. In:  Wood JBJ editors. Lactic Acid Bacteria in Health and Disease. vol 1:London, UK: Elsevier Applied Science; 1992;p. 151–170
  8. Havenaar R, Ten Brink B, Huis in't Veld JHJ. Selection of strains for probiotic use. In:  Fuller R editors. Probiotics: The Scientific Basis. London, England: Chapman & Hall; 1992;p. 151–170
  9. Elo S, Saxelin M, Salminen S. Attachment of Lactobacillus casei strain GG to human colon carcinoma cell line Caco-2: Comparison with other dairy strains. Lett Appl Microbiol. 1991;13:154–156
  10. Conconnier M, Klaenhammer TR, Kerneis S, et al.  Protein-mediated adhesion of Lactobacillus acidophilus BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. Appl Environ Microbiol. 1992;58:2034–2039
  11. Bernet M, Brassart D, Neeser J, et al.  Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol. 1993;59:4121–4128
  12. Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987;70:1–12
  13. Bouhnik Y, Pochart P, Marteau P, et al.  Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterol. 1992;102:875–878
  14. Goldin BR, Gorbach SL, Saxelin M, et al.  Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992;37:121–128
  15. Pochart P, Marteau P, Bouhnik Y, et al.  Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: An in vivo study using intestinal perfusion. Am J Clin Nutr. 1992;55:78–80
  16. Kullen MJ, Amann MM, O'shaughnessy MJ, et al.  Differentiation of ingested and endogenous bifidobacteria by DNA fingerprinting demonstrates the survival of an unmodified strain in the gastrointestinal tract of humans. J Nutr. 1997;127:89–94
  17. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J Appl Bacteriol. 1993;75:95–107
  18. Centers for Disease Control and Prevention . Recommendation for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR. 1995;44(No. RR-12):1
  19. McFarland LV. Biotherapeutic agents for Clostridium difficile-associated disease. In:  Elmer GW,  McFarland LV,  Surawicz CM editor. Biotherapeutic Agents and Infectious Diseases. Totowa, NJ: Humana Press; 1999;p. 159–193
  20. Buts J. Mechanisms of action of biotherapeutic agents. In:  Elmer GW, et al. editor. Biotherapeutic Agents and Infectious Diseases. Totowa, NJ: Humana Press; 1999;p. 27–46
  21. Kroger M, Kurmann JA, Rasic JL. Fermented milks—Past, present, and future. Food Technol. 1989;43:92–99
  22. Hume ME, Corrier DE, Nisbet DJ, et al.  Early Salmonella challenge time and reduction in chick cecal colonization following treatment with a characterized competitive exclusion culture. J Food Protect. 1998;61:673–676
  23. Donohue DC, Salminen S. Safety of probiotic bacteria. Asia Pacific J Clin Nutr. 1996;5:25–28
  24. Salminen S, von Wright A, Morelli L, et al.  Demonstration of safety of probiotics—A review. Int J Food Microbiol. 1998;44:93–106
  25. Rautio M, Jousimies-Somer H, Kauma H, et al.  Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28:1159–1160
  26. Brook I, Frazier EH. Significant recovery of nonsporulating anaerobic rods from clinical specimens. Clin Infect Dis. 1993;16:476–480
  27. Lidbeck A, Nord CE. Lactobacilli and the normal human anaerobic microflora. Clin Infect Dis. 1993;16(suppl):181–187
  28. Moore WEC, Holdeman LV. Human fecal flora: The normal flora of 20 Japanese-Hawaiians. Appl Microbiol. 1974;27:961–979
  29. Moore WEC, Cato EP, Holdeman LV. Anaerobic bacteria of the gastrointestinal flora and their occurrence in clinical infections. J Infect Dis. 1969;119:641–649
  30. Saxelin M, Rautelin H, Salminen S, et al.  Safety of commercial products with viable Lactobacillus strains. Infect Dis Clin Pract. 1996;5:331–335
  31. Kandler O, Weiss N. Genus Lactobacillus. In:  Sneath PHA, et al. editor. Bergey's Manual of Systematic Bacteriology. vol 2:Baltimore, MD: Williams & Wilkins; 1986;p. 1209–1234
  32. Davies AJ, James PA, Hawkey PM. Lactobacillus endocarditis. J Infect. 1986;12:169–174
  33. Rao GG, Short A, Carmichael DJS. CAPD peritonitis caused by vancomycin-resistant lactobacilli. Nephrol Dial Transplant. 1990;5:235–236
  34. Chomarat M, Espinouse D. Lactobacilus rhamnosus septicemia in patients with prolonged aplasia receiving ceftazidime-vancomycin. Eur J Clin Microbiol Infect Dis. 1991;10:44
  35. Griffiths JK, Daly JS, Dodge RA. Two cases of endocarditis due to Lactobacillus species: Antimicrobial susceptibility, review, and discussion of therapy. Clin Infect Dis. 1992;15:250–255
  36. Namnyak SS, Blair ALT, Hughes DF, et al.  Fatal lung abscess due to Lactobacillus ss rhamnosus. Thorax. 1992;47:666–667
  37. Bayer AS, Chow AW, Ishida K, et al.  Therapy of experimental infective endocarditis due to antibiotic-tolerant Lactobacillus plantarum—Bactericidal synergy of penicillin plus gentamicin. Chemother. 1981;27:444–451
  38. Sussman JI, Baron EJ, Goldberg SM, et al.  Clinical manifestations and therapy of Lactobacillus endocarditis: report of a case and review of the literature. Rev Infect Dis. 1986;8:771–776
  39. Sodeman TM, Schafer K, Bentz R, et al.  Infection due to Bifidobacterium eriksonnei. Am J Clin Pathol. 1973;59:143; (abstr)
  40. Thomas AV, Sodeman TH, Bentz RR. Bifidobacterium (Actinomyces) eriksonii infection. Am Rev Respir Dis. 1974;110:663–668
  41. Green SL. Case report: Fatal anaerobic pulmonary infection due to Bifidobacterium eriksonii. Postgrad Med. 1978;63:187–189
  42. Scardovi V. Genus Bifidobacterium. In:  Sneath PHA, et al. editor. Bergey's Manual of Systematic Bacteriology. vol 2:Baltimore, MD: Williams & Wilkins; 1986;p. 1418–1434
  43. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;9:40–65
  44. Martin SW, Heatherington AC, Elmer GW. Pharmacokinetics of biotherapeutic agents. In:  Elmer GW, et al. editor. Biotherapeutic Agents and Infectious Diseases. Totowa, NJ: Humana Press; 1999;p. 47–84
  45. Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infections. Bull Inst Pasteur. 1994;92:45–67
  46. Dunn SR, Simenhoff ML, Ahmed KE, et al.  Effect of oral administration of freeze-dried Lactobacillus acidophilus on small bowel bacterial overgrowth in patients with end stage kidney disease: Reducing uremic toxins and improving nutrition. Int Dairy J. 1998;8:545–553
  47. Dunn SR, Simenhoff ML, Fitzpatrick ME, et al.  Reduction of an endogenous uremic toxin (dimethylamine) and a carcinogen (nitrosodimethylamine) and improvement of nutritional status in 24 dialysis patients treated with oral Lactobacillus acidophilus. J Am Soc Nephrol. 1998;9:145; (abstr)
  48. Schleifer CR, Benz RL, McAlack R, et al.  Lactobacillus acidophilus peritonitis in CAPD. Peritoneal Dial Int. 1989;9:222–223
  49. Sanyal D, Bhandari S. CAPD peritonitis caused by Lactobacillus rhamnosus. J Hosp Infect. 1992;22:325–327
  50. Klein G, Zill E, Schindler R, et al.  Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient: Organism identification, antibiotic therapy, and case report. J Clin Microbiol. 1998;36:1781–1783
  51. Vollaard EJ, Clasener HAL. Colonization resistance. Antimicrob Agents Chemother. 1994;38:409–414
  52. Nurmi E, Nuotio L, Schneitz C. The competitive exclusion concept: development and future. Int J Food Microbiol. 1992;15:237–240
  53. Wilson KH, Silva J, Fekety FR. Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun. 1981;34:626–628
  54. Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: Mechanism of restoring floral homeostasis. Am Surg. 1981;47:178–183
  55. Schwan A, Sjolin S, Trottestam U, et al.  Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scan J Infect Dis. 1984;16:211–215
  56. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156–1160
  57. Paterson DL, Iredell J, Witby M. Putting back the bugs: Bacterial treatment relieves chronic diarrhea. Med J Austr. 1994;160:232–233
  58. Borody TJ. “Flora power”—Fecal bacteria cure chronic C. difficile diarrhea. Aust J Gastroenterol. 2000;95:3028–3029
  59. Fuller R. Probiotics in human medicine. Gut. 1991;32:439–442
  60. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;130:396–402
  61. Reddy BS. Prevention of colon cancer by pre- and probiotics: Evidence from laboratory studies. Br J Nutr. 1998;80(suppl):219–223
  62. Blocksma N, De Heer E, Van Dijk H, et al.  Adjuvanticity of lactobacilli I. Differential effects of viable and killed bacteria. Clin Exp Immunol. 1979;37:367–375
  63. Solis Pereyra B, Lemonnier D. Induction of human cytokines by bacteria used in dairy foods. Nutr Res. 1993;13:1127–1140
  64. Majamaa H, Isolauri E. Probiotics: A novel approach in the management of food allergy. J Allergy Clin Immunol. 1997;99:179–185
  65. Vanderhoof JA, Whitney DB, Antonson DL, et al.  Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135:564–568
  66. Hilton E, Isenberg HD, Slperstein P, et al.  Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med. 1992;116:353–357
  67. McFarland LV, Surawica CM, Greenberg RN, et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–1918
  68. Gorbach SL, Chang T-W, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987;2:1519; (letter)
  69. Bennett RG, Gorbach SL, Goldin BR, et al.  Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG. Nutr Today. 1996;31(suppl):35S–38S
  70. Alak JIB, Wolf BW, Mdurvwa EG, et al.  Supplementation with Lactobacillus reuteri or Lactobacillus acidophilus reduces intestinal shedding of Cryptosporidium parvum oocyts in immunodeficient C57BL/6 mice. Cell Mol Biol. 1999;45:855–863
  71. Canducci F, Armuzzi A, Cremonini F, et al.  A lyophilized and inactivated culture of lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2000;14:1625–1629
  72. Loguercio C, Abbiati R, Rinaldi M, et al.  Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol. 1995;23:39–46
  73. Gionchetti P, Rizzello F, Venturi A, et al.  Probiotics in infective diarrhoea and inflammatory bowel disease. J Gastroenterol Hepatol. 2000;15:489–493
  74. Siu YK, Ng PC, Fung SCK, et al.  Double blind, randomised, placebo controlled study of oral vancomycin in the prevention of necrotising enterocolitis in preterm, very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 1998;79:105–109
  75. Caplan MS, Jilling T. Neonatal necrotizing enterocolitis: Possible role of probiotic supplementation. J Pediatr Gastroenterol Nutr. 2000;30:18–22
  76. Simenhoff ML, Dunn SR. Altered gut flora in uremia. J Renal Nutr. 1996;6:68–74
  77. Goldin BR, Gorbach SL. The effect of oral administration of Lactobacillus and antibiotics on intestinal bacterial activity and chemical induction of large bowel tumors. Dev Industr Microbiol. 1984;25:139–150
  78. Reid G, Chan RCY, Bruce AW, et al.  Prevention of urinary tract infection in rats with an indigenous Lactobacillus casei strain. Infect Immun. 1985;49:320–324
  79. Winberg J, Herthelius-Elman M, Mollby R, et al.  Pathogenesis of urinary tract infection—Experimental studies of vaginal resistance to colonization. Pediatr Nephrol. 1993;7:509–514
  80. Simenhoff ML. Role of the bowel in uremia. Curr Nephrol. 1986;9:107–148
  81. Canganella F, Paganini S, Ovidi M. A microbiological investigation on probiotic pharmaceutical products used for human health. Microbiol Res. 1997;152:171–179
  82. Clements ML, Levine MM, Black RE, et al.  Lactobacillus prophylaxis for diarrhea due to enterotoxigenic. Escherichia coli. 1981;20:104–108
  83. Clements ML, Levine MM, Ristaino PA. Exogenous lactobacilli fed to man—their fate and ability to prevent diarrheal disease. Prog Fd Nutr Sci. 1983;7:29–37
  84. de Dios Pozo-Olano J, Warram JH, Gomez RG, et al.  Effect of a lactobacilli preparation on traveler's diarrhea: a randomized, double blind clinical trial. Gastroenterol. 1978;74:829–830
  85. Campbell JM, Bauer LL, Fahey GC, et al.  Selected fructooligosaccharide (1-kestose, nystose, 1F-β-fructofuranosylnystose) composition of foods and feeds. J Agric Food Chem. 1997;45:3076–3082
  86. Coussement PAA. Inulin and oligofructose: Safe intakes and legal status. J Nutr. 1999;129:1412–1417
  87. Moshfegh AJ, Friday JE, Goldman JP, et al.  Presence of inulin and oligofructose in the diets of Americans. J Nutr. 1999;129:1407–1411
  88. Bouhnik Y, Vahedi K, Achour L, et al.  Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr. 1999;129:113–116
  89. Cockram DB, Hensley MK, Rodriguez M, et al.  Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. J Renal Nutr. 1998;8:25–33
  90. Molis C, Flourie B, Ouarne F, et al.  Digestion, excretion, and energy value of fructooligosaccharides in healthy human adults. Am J Clin Nutr. 1996;64:324–328
  91. Mitsuoka T, Hidaka H, Eida T. Effect of fructo-oligosaccharides on intestinal flora. Die Nahrung. 1987;31:427–436
  92. Van den Heuvel EGHM, Muys T, van Kokkum W, et al.  Oligofructose stimulates calcium absorption in adolescents. Am J Clin Nutr. 1999;69:544–548
  93. Garleb KA, Snook JT, Marcon MJ, et al.  Effect of fructooligosaccharide containing enteral formulas on subjective tolerance factors, serum chemistry profiles, and faecal bifidobacteria in healthy adult male subjects. Microb Ecol Health Dis. 1996;9:279–285
  94. Roberfroid M. Dietary fiber, inulin, and oligofructose: A review comparing their physiological effects. Crit Rev Food Sci Nutr. 1993;33:103–148
  95. Williams CM. Effects of inulin on lipid parameters in humans. J Nutr. 1999;129:1471–1473
  96. Campbell J, Fahey GC, Wolf BW. Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats. J Nutr. 1997;127:130–136
  97. Younes H, Garleb K, Behr S, et al.  Fermentable fibers or oligosaccharides reduce urinary nitrogen excretion by increasing urea disposal in the rat cecum. J Nutr. 1995;125:1010–1016
  98. Ibrahim SA, Bezkorovainy A. Inhibition of Escherichia coli by bifidobacteria. J Food Protect. 1993;56:713–715
  99. Meghrous J, Euloge P, Junelles AM, et al.  Screening of Bifidobacterium strains for bacteriocin production. Biotechnol Lett. 1990;12:575–580
  100. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol. 1994;77:412–420
  101. Rao AV, Koo MM. Effect of oral administration of bifidobacteria and Neosugar on plasma ammonia concentration in CF1 mice. Int J Food Sci Nutr. 1992;43:9–17
  102. Krause LJ, Forsberg CW, O'Connor DL. Feeding human milk to rats increases Bifidobacterium in the cecum and colon which correlates with enhanced folate status. J Nutr. 1996;126:1505–1511
  103. Jiang T, Mustapha A, Savalano DA. Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J Dairy Sci. 1996;79:750–757
  104. Hidaka H, Eida T, Takizawa T, et al.  Effects of fructooligosaccharides on intestinal flora and human health. Bifidobacteria Microflora. 1986;3:37–50
  105. Roberfroid MB. Caloric value of inulin and oligofructose. J Nutr. 1999;129:1436–1437
  106. Stone WJ. Therapy of constipation in patients with chronic renal failure. Dialy Transplan. 1977;6:30–32
  107. Chambers J. Bowel management in dialysis patients. Am J Nursing. 1983;83:1051–1052
  108. Hammer J, Oesterreicher C, Hammer K. Chronic gastrointestinal symptoms in hemodialysis patients. Wien Klin Wochenschr. 1998;110:287–291
  109. St. Peter WL, Clark JL, Levos OM. Drug therapy in haemodialysis patients: Special considerations in the elderly. Drugs Aging. 1998;12:441–459
  110. Odaka K, Inamoto H, Sata K, et al.  T: Constipation and dietary fiber in dialysis patients. 2. Incidence and causative factors of constipation. Japan Soc Dial Therapy. 1989;22:995–998
  111. American Gastroenterological Association . American Gastroenterological Association medical position statement: Guidelines on constipation. Gastroenterol. 2000;119:1761–1778
  112. Chen H-L, Lu Y-H, Lin J-J, et al.  Effects of fructooligosaccharide on bowel function and indicators of nutritional status in constipated elderly men. Nutr Res. 2000;20:1725–1733
  113. Hond ED, Geypens B, Ghoos Y. Effect of high performance chicory inulin on constipation. In: Nutr Res. 20:2000;p. 731–736
  114. Briet F, Achour L, Flourie B, et al.  Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. Eur J Clin Nutr. 1995;49:501–507
  115. Hata Y, Nakajima K. Studies on relationship between intake of fructooligosaccharides and abdominal symptoms—Estimation of the maximum non-effective dose and 50% laxative effective dose. Geriatr Med. 1985;23:817–828
  116. Clausen MR, Jorgensen J, Mortensen PB. Comparison of diarrhea induced by ingestion of fructooligosaccharide Idolax and disaccharide lactulose. Dig Dis Sci. 1998;43:2696–2707
  117. Smith CJ, Bryant MP. Introduction to metabolic activities of intestinal bacteria. Am J Clin Nutr. 1979;32:149–157
  118. Simenhoff ML, Saukkonen JJ, Burke JF, et al.  Bacterial populations of the small intestine in uremia. Nephron. 1978;22:63–68
  119. Williams RE, Hill MJ, Drasar BS. The influence of intestinal bacteria on the absorption and metabolism of foreign compounds. J Clin Pathol. 1971;24:125–129
  120. Onwulata CI, Ramkishan Rao D, Vankineni P. Relative efficiency of yogurt, sweet acidophilus milk, hydrolyzed-lactose milk, and a commercial lactase tablet in alleviating lactose maldigestion. Am J Clin Nutr. 1989;49:1233–1237
  121. Isolauri E, Huntunen M, Rautanen T, et al.  A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatr. 1991;88:90–97
  122. Isolauri E, Kaila M, Mykkanen H, et al.  Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci. 1994;39:2595–2600
  123. Shornikova A-V, Casas IA, Mykkanen H, et al.  Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 1997;16:1103–1107

☆ Address reprint requests to JoMay Chow, PhD, Strategic-Discovery Research and Development, Ross Products Division, Abbott Laboratories 105670/RP3-2, 625 Cleveland Ave, Columbus, OH 43215-1724.

PII: S1051-2276(02)44207-0

Journal of Renal Nutrition
Volume 12, Issue 2 , Pages 76-86 , April 2002

Article Tools

* Image Usage & Resolution